Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs AstraZeneca plc (AZN) Price & Performance

YieldMax AMZN Option Income Strategy ETF
AstraZeneca plc

Price performance

Price movement over the last 24 hours

Key statistics

YieldMax AMZN Option Income Strategy ETF vs AstraZeneca plc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.73, while AstraZeneca plc trades at $169.42 (market cap $262.75B). The key difference: AstraZeneca plc pays a 1.84% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMZYAZN
Sector
Income / Options OverlayHealth
52-Week High
$16.61$209.48
52-Week Low
$10.26$137.44
Market Cap
$262.75B
Enterprise Value
$289.00B
Dividend Yield
1.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.

The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.

AstraZeneca plc

AstraZeneca (AZN) trades at $171.61, down 3.85% following a Phase 3 clinical trial failure for its Wainua heart drug. The stock faces bearish technical signals with support at $167 and resistance at $177. Fundamentally, the company maintains strong profitability with 17.19% net margins and robust revenue growth, reaching $58.74B in 2025. Analyst consensus remains positive with 47.5% buy ratings despite recent setbacks.

The outlook remains cautiously optimistic as AstraZeneca's core business fundamentals remain intact with improving cash flow and debt reduction. However, pipeline execution risks and clinical trial uncertainties present near-term headwinds. Long-term investors may find value at current levels given the company's strong market position and financial health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN